Open AccessLevonadifloxacin, a Novel Benzoquinolizine Fluoroquinolone, Modulates Lipopolysaccharide-Induced Inflammatory Responses in Human Whole-Blood Assay and Murine Acute Lung Injury Model
Author(s) -
Anasuya Patel,
Ganesh V. Sangle,
Jinal Trivedi,
Sushant Shengule,
Deepak Thorve,
Mohan Patil,
Nitin Deshmukh,
Bhushan Choudhari,
Avinash Karade,
Sapna Gupta,
Sachin Bhagwat,
Mahesh Patel
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00084-20
Subject(s) - proinflammatory cytokine , lipopolysaccharide , myeloperoxidase , whole blood , white blood cell , medicine , pharmacology , lung , immunology , inflammation , cytokine
Fluoroquinolones are reported to possess immunomodulatory activity; hence, a novel benzoquinolizine fluoroquinolone, levonadifloxacin, was evaluated in lipopolysaccharide-stimulated human whole-blood (HWB) and mouse acute lung injury (ALI) models. Levonadifloxacin significantly mitigated the inflammatory responses in an HWB assay through inhibition of proinflammatory cytokines and in the ALI model by lowering lung total white blood cell count, myeloperoxidase, and cytokine levels. The immunomodulatory effect of levonadifloxacin, along with promising antibacterial activity, is expected to provide clinical benefits in the treatment of infections.